Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H]GBR 12783 or [3H]mazindol
- PMID: 2141637
Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H]GBR 12783 or [3H]mazindol
Abstract
We have investigated the thermodynamic properties of the binding of substrates and uptake blockers to the specific sites labeled with a tritiated dopamine uptake inhibitor (i.e., 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine ([3H] GBR 12783) or [3H]mazindol) using striatal membrane preparations. Raising the incubation temperature from 0 degrees C to 25 degrees C or 37 degrees C resulted in an increase in the dissociation constant of both [3H]mazindol and [3H]GBR 12783 for their specific sites of binding present in membrane suspensions obtained from either rabbit or rat striatum. However, maximal concentrations of binding sites were not affected by temperature. At all tested temperatures, both substrates and carrier blockers competed with either [3H]mazindol or [3H]GBR 12783 in a monophasic fashion, with Hill coefficients close to unity. Raising the temperature induced little or no increase in inhibition constants (Ki) for substrates (Ki ratio 37/0 degrees C less than 2.5). This is consistent with the mild increase of the Michaelis constant of dopamine for the neuronal uptake system when the incubation temperature was raised from 12.5 to 37 degrees C (from 126 to 406 nM). In contrast, increasing the temperature resulted in a more important increase in the Ki of uptake inhibitors (33 greater than Ki ratio greater than 5). Thermodynamic calculations showed that the binding of substrates is generally characterized by a mild decrease in enthalpy (range, -2- -6 kcal/mol) associated with an increase in entropy, whereas binding of uptake inhibitors led to a decrease of both parameters.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
[3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites.Mol Pharmacol. 1984 Jul;26(1):35-44. Mol Pharmacol. 1984. PMID: 6087116
-
Quantitative autoradiography of the dopamine uptake complex in rat brain using [3H]GBR 12935: binding characteristics.Brain Res. 1991 Feb 1;540(1-2):1-13. doi: 10.1016/0006-8993(91)90486-f. Brain Res. 1991. PMID: 1829013
-
[3H]GBR-12935 binding to dopamine uptake sites in rat striatum.Neuropsychobiology. 1990-1991;23(4):177-81. doi: 10.1159/000119449. Neuropsychobiology. 1990. PMID: 2130286
-
Photoaffinity labeling of the dopamine reuptake carrier protein with 3-azido[3H]GBR-12935.Mol Pharmacol. 1991 Apr;39(4):429-35. Mol Pharmacol. 1991. PMID: 2017146
-
Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding.J Pharmacol Exp Ther. 1988 Apr;245(1):199-210. J Pharmacol Exp Ther. 1988. PMID: 3129549
Cited by
-
Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.Mol Pharmacol. 2011 Mar;79(3):520-32. doi: 10.1124/mol.110.069039. Epub 2010 Dec 13. Mol Pharmacol. 2011. PMID: 21149640 Free PMC article.
-
Dopamine releasing effect of phenylbiguanide in rat striatal slices.Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):666-72. doi: 10.1007/BF00164581. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1635590
-
Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter-mediated nonquantal dopamine release.Physiol Rep. 2021 Nov;9(21):e15088. doi: 10.14814/phy2.15088. Physiol Rep. 2021. PMID: 34762352 Free PMC article.
-
Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935.Naunyn Schmiedebergs Arch Pharmacol. 1992 Mar;345(3):309-18. doi: 10.1007/BF00168692. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1620235
-
Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites.Psychopharmacology (Berl). 1992;107(2-3):186-94. doi: 10.1007/BF02245136. Psychopharmacology (Berl). 1992. PMID: 1377395